Abstract
Held virtually on March 30-31, 2021, the 6th Oligonucleotide & Precision Therapeutics (OPT) Congress, organized by Cambridge Healthtech Institute (CHI), covered advances in science and technologies that are propelling innovation across the oligonucleotide industry. Welcoming 300 attendees and 25 speakers, the event offered several modes of content presentation (live, prerecorded, on-demand, panel discussions, group breakout sessions and posters) and featured 2 focused conference streams: day 1 examined oligonucleotide discovery and delivery, and day 2 addressed chemistry, manufacturing and controls (CMC) and regulatory strategies. This report summarizes several presentations given during the congress.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
